The object is to have a stem-cell treatment ready for human trials within three years, said Mohammad A. El-Kalay, EyeCyte chief executive and a veteran of several cell-therapy companies.
FORBES: Pfizer Eyes New Use For Stem Cells
应用推荐
模块上移
模块下移
不移动